Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Rating of “Buy” by Brokerages

Quince Therapeutics, Inc. (NASDAQ:QNCX) has been given a consensus rating of “Buy” by the six analysts that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $9.50.

A number of equities analysts have recently issued reports on the stock. D. Boral Capital restated a “buy” rating and set a $12.00 target price on shares of Quince Therapeutics in a research report on Thursday, January 2nd. RODMAN&RENSHAW upgraded shares of Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 29th. Rodman & Renshaw began coverage on shares of Quince Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $11.00 target price for the company. Maxim Group started coverage on Quince Therapeutics in a report on Thursday, November 7th. They set a “buy” rating and a $6.00 price target on the stock. Finally, Brookline Capital Management initiated coverage on Quince Therapeutics in a research note on Wednesday, December 18th. They set a “buy” rating and a $9.00 price objective for the company.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Quince Therapeutics stock. Geode Capital Management LLC raised its holdings in Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 339,125 shares of the company’s stock after purchasing an additional 66,170 shares during the quarter. Geode Capital Management LLC owned 0.78% of Quince Therapeutics worth $263,000 as of its most recent filing with the Securities and Exchange Commission. 30.75% of the stock is currently owned by institutional investors.

Quince Therapeutics Trading Down 3.1 %

NASDAQ:QNCX opened at $1.88 on Thursday. The company has a market capitalization of $82.72 million, a PE ratio of -1.52 and a beta of 0.64. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.45. The stock’s 50 day moving average price is $1.85 and its 200 day moving average price is $1.13. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.